| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
50,000,000 |
| Market
Cap: |
1.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$24.53 - $38.65 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunocore Holdings is a late-stage biotechnology company focusing on the development of a class of T cell receptors, or TCR, bispecific immunotherapies called ImmTAX, Immune mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, infectious and autoimmune. Co.'s platforms include: ImmTAC, which focuses on the treatment of solid tumors; ImmTAV, which includes IMC-I109V, its ImmTAV molecule targeting a conserved hepatitis B virus envelope antigen; and ImmTAAI, which utilizes its ImmTAX platform to generate product candidates designed to provide targeted immunosuppression for the treatment of autoimmune diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
807,338 |
807,338 |
| Total Buy Value |
$0 |
$0 |
$23,993,224 |
$23,993,224 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
135,000 |
135,000 |
135,000 |
263,750 |
| Total Sell Value |
$4,814,609 |
$4,814,609 |
$4,814,609 |
$13,815,129 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
5 |
5 |
5 |
10 |
| End Date |
2025-07-20 |
2025-04-18 |
2024-10-18 |
2023-10-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Berman David M |
HEAD OF R&D |
• – – |
2025-09-30 |
4 |
AS |
$35.23 |
$2,178,940 |
D/D |
(61,849) |
0 |
|
-8% |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-30 |
4 |
OE |
$17.46 |
$1,079,884 |
D/D |
61,849 |
61,849 |
|
- |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-15 |
4 |
AS |
$35.01 |
$7,002 |
D/D |
(200) |
0 |
|
-3% |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-15 |
4 |
OE |
$17.46 |
$3,492 |
D/D |
200 |
200 |
|
- |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-12 |
4 |
AS |
$35.63 |
$803,699 |
D/D |
(22,532) |
0 |
|
-5% |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-12 |
4 |
OE |
$17.46 |
$393,409 |
D/D |
22,532 |
22,532 |
|
- |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-11 |
4 |
AS |
$36.28 |
$692,259 |
D/D |
(19,081) |
0 |
|
-8% |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-11 |
4 |
OE |
$17.46 |
$333,154 |
D/D |
19,081 |
19,081 |
|
- |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-10 |
4 |
AS |
$36.12 |
$1,132,709 |
D/D |
(31,338) |
0 |
|
-8% |
|
| Berman David M |
HEAD OF R&D |
• – – |
2025-09-10 |
4 |
OE |
$17.46 |
$547,161 |
D/D |
31,338 |
31,338 |
|
- |
|
| Baker Julian |
|
– • – |
2025-03-17 |
4 |
B |
$29.56 |
$23,993,224 |
I/I |
807,338 |
2,144,060 |
0.01 |
17% |
|
| Baker Julian |
|
– • – |
2024-05-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,515,318 |
|
-34% |
|
| St Leger Tina Amber |
CHIEF HR OFFICER |
• – – |
2024-04-01 |
4 |
AS |
$64.06 |
$280,263 |
D/D |
(4,375) |
0 |
|
-40% |
|
| St Leger Tina Amber |
CHIEF HR OFFICER |
• – – |
2024-04-01 |
4 |
OE |
$29.87 |
$130,681 |
D/D |
4,375 |
4,375 |
|
- |
|
| Berman David M |
HEAD OF R&D |
• – – |
2024-02-28 |
4 |
AS |
$67.61 |
$2,504,158 |
D/D |
(36,509) |
0 |
|
-45% |
|
| Berman David M |
HEAD OF R&D |
• – – |
2024-02-28 |
4 |
OE |
$17.46 |
$637,447 |
D/D |
36,509 |
36,509 |
|
- |
|
| Berman David M |
HEAD OF R&D |
• – – |
2024-02-27 |
4 |
AS |
$69.45 |
$3,893,030 |
D/D |
(54,938) |
0 |
|
-46% |
|
| Berman David M |
HEAD OF R&D |
• – – |
2024-02-27 |
4 |
OE |
$17.46 |
$959,217 |
D/D |
54,938 |
54,938 |
|
- |
|
| Berman David M |
HEAD OF R&D |
• – – |
2024-02-26 |
4 |
AS |
$70.60 |
$2,017,288 |
D/D |
(28,553) |
0 |
|
-47% |
|
| Berman David M |
HEAD OF R&D |
• – – |
2024-02-26 |
4 |
OE |
$17.46 |
$498,535 |
D/D |
28,553 |
28,553 |
|
- |
|
| St Leger Tina Amber |
Chief HR Officer |
• – – |
2024-01-03 |
4 |
AS |
$69.85 |
$305,781 |
D/D |
(4,375) |
0 |
|
-21% |
|
| St Leger Tina Amber |
Chief HR Officer |
• – – |
2024-01-03 |
4 |
OE |
$29.87 |
$130,681 |
D/D |
4,375 |
4,375 |
|
- |
|
| Ratcliffe Peter John |
Director |
– • – |
2024-01-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
333 |
|
-20% |
|
| Di Donato Brian |
Chief Financial OfficerOfficer |
• – – |
2024-01-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,230 |
|
-20% |
|
| Bell John Irving |
Director |
– • – |
2024-01-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,452 |
|
-20% |
|
25 Records found
|
1
|
Page 1 of 1 |
|
|
0.03 (0.09%) 
